Pulmonary arterial hypertension PAH
Conditions
Interventions
None listed
Sponsors
Arai Yoko
Eligibility
Inclusion criteria
Inclusion criteria: The pilot and main web survey: the study participants must satisfy all of the following inclusion criteria: 1.Physicians who have experienced PAH treatment at least one adult PAH patient (ages 18 years old and over) using PAH-targeted drugs in the last 5 years 2.Physicians who have experienced in prescription and determination of PAH treatment in the last 5 years 3.Physicians are primarily affiliated with the following departments as their current facilities -Respiratory internal medicine/Cardiovascular internal medicine/Pediatric cardiology/Rheumatology/Internal medicine for connective tissue/Dermatology and specializing in these areas within general internal medicine 4. Physicians who provide informed consent to participate in the study.
Exclusion criteria
Exclusion criteria: The pilot and main web survey: the study participants who satisfy any of the following criteria will be excluded from the study. 1.Physicians who have been employed by a pharmaceutical company or have been a consultant of a pharmaceutical company in the last 5 years 2.Physicians who have experienced prescribing PAH-targeted drugs, but no experience in treatment decision in the last 5 years 3.Physicians who have neither experience in prescribing PAH-targeted drugs nor in treatment decision in the last 5 years 4.Physicians are primarily affiliated with the following departments as their current facilities; -Neurology/Ophthalmology: specializing in these areas within general internal medicine
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1.Basic characteristics of physicians 2.Basic characteristics of PAH patients from a physician perspective 3.Principles of disease management and treatment regimens 4.Clinical information describing drivers and barriers for the treatment decision | — |
Secondary
| Measure | Time frame |
|---|---|
| The data will be stratified to generate two subgroups, regularly treating and occasionally treating physicians groups. Cross tabultion analysis will be performed to identify any factors associated with treatment decision and disease management. | — |
Contacts
Public ContactIchiro Tazaki
MSD K.K.
Outcome results
None listed